Tamoxifen or Cyproterone Acetate in Combination with Buserelin Are Ineffective in Patients with Pancreatic Adenocarcinoma
Clicks: 294
ID: 268240
1993
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
294 views
51 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #7 of 7 articles by views in oncology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Experimental evidence and preliminary clinical data suggest a responsiveness of pancreatic adenocarcinoma to sex hormones and LH-RH agonists. In this study, we investigated the effect of the antiestrogen tamoxifen and the anti-androgen cyproterone acetate in combination with the LH-RH agonist buserelin in 9 patients with unresectable pancreatic adenocarcinoma. In all patients the disease was progressive under this therapeutic regimen. In conclusion, complete androgen blockade and antiestrogens in combination with LH-RH agonist cannot be recommended in patients with widespread pancreatic adenocarcinoma.
| Reference Key |
arnold1993oncologytamoxifen
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | B. Swarovsky,M. Wolf,K. Havemann,R. Arnold;B. Swarovsky;M. Wolf;K. Havemann;R. Arnold; |
| Journal | oncology |
| Year | 1993 |
| DOI |
10.1159/000227184
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.